A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
This study will evaluate the efficacy and safety of intravenous RC48-ADC in local advanced or metastatic gastric patients with the overexpression of HER2.
Gastric Cancer|HER2 Overexpressing Gastric Carcinoma
DRUG: RC48-ADC
Objective Response Rate （ORR）, Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR), up to 24 months
Progression Free Survival (PFS) as Assessed by investigator, Tumor response was assessed by investigator according to RECIST v1.1, up to 24 months|Overall Survival(OS), OS was defined as the time from the first study treatment to the date of death from any cause, up to 24 months
This study will evaluate the efficacy and safety of intravenous RC48-ADC in local advanced or metastatic gastric patients with the overexpression of HER2.